News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
The Center for Breakthrough Medicines and Penn partner in the manufacturing of gene therapies
Penn’s Innovation in Process Science combines with CBM manufacturing capability to develop large-scale gene therapy manufacturing capacity, testing, and analytics
Halting Progress and Happy Accidents: How mRNA vaccines were made
A New York Times feature on the history, research, challenges, and timeline to make the COVID-19 mRNA vaccines.
Cogwear is featured on the cover of the Journal of Precision Medicine
The Journal of Precision Medicine highlighted Penn spinout Cogwear’s novel technology for behavioral health applications.
Moderna forms oncology collaboration with Carisma Therapeutics
Moderna will collaborate with Penn spinout Carisma Therapeutics to discover, develop and commercialize in-vivo engineered chimeric antigen receptor monocyte therapeutics for the treatment of cancer.
From foundational discoveries to profound impact
Without the mRNA technology foundation laid by Karikó and Weissman, the Pfizer/BioNTech and Moderna vaccines being deployed across the world would not exist.
Technology used in mRNA COVID vaccines offers hope for treatment of millions with heart disease, study suggests
Combining technologies that proved hugely success against cancer and in COVID-19 vaccines, researchers at Penn have shown they can effectively treat a leading cause of heart disease.
Vaccine-like mRNA injection can be used to make CAR T cells in the body
The researchers, whose work is published in Science, demonstrated the new approach with an mRNA preparation that reprograms T cells—a powerful type of immune cell—to attack heart fibroblast cells.
Lessons in resilience: What changes did you make during the pandemic that you’ll keep with you?
These leaders made changes to workplace communication, collaboration and their personal lives.
Katalin Karikó, PhD, featured on the cover of Newsweek as one of America’s Greatest Disruptors
She was described as being one of the 50 visionaries whose career-long actions have had far-reaching impact.
iECURE partners to develop next-generation liver-targeted lipid nanoparticles with Penn
iECURE announced that it has entered into an exclusive agreement with Penn to develop next-generation lipid nanoparticles (LNP) for liver gene editing applications.